A Phase I Study of the Raf Kinase/VEGFR Inhibitor BAY 43-9006 in Combination With the Proteasome Inhibitor PS-341 in Patients With Advanced Malignancies.
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2013
At a glance
- Drugs Bortezomib (Primary) ; Sorafenib (Primary)
- Indications Chronic lymphocytic leukaemia; Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 21 Jun 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.